CVS Health raises annual profit forecast as turnaround gathers steam

By Manas Mishra
(Reuters) - CVS Health raised its full-year profit forecast on Thursday following strong performance across its businesses, signaling an early recovery after a series of troubles hit the healthcare conglomerate last year.
Shares of the company jumped 8.4% to $72.30 in premarket trading.
The shares fell over 40% last year due to weak performance in the company's insurance and pharmacy businesses and multiple cuts to its profit outlook, but have pared most of those losses this year following a better-than-expected earnings report in February.
CEO David Joyner, who took the helm in October, has laid out cost-cutting plans and reshuffled top management positions to help the company navigate one of the most challenging periods in its six-decade history.
On Thursday, CVS Health's adjusted quarterly profit again beat estimates, as the company spent less on its members' medical care than Wall Street had expected, a likely relief for investors after UnitedHealth cut its forecast last month, citing elevated costs.
The company said it would exit the individual exchange business, where it sells plans directly to individuals through Obamacare exchanges -- its latest effort to streamline operations.
CVS' pharmacy benefit management unit also plans to drop Eli Lilly's weight-loss drug Zepbound as a preferred product from its list of drugs eligible for reimbursement, and would retain Novo Nordisk's Wegovy. "Zepbound will be excluded on July 1, and our clients will save a significant amount of money in this therapy class," a CVS spokesperson said.
CVS' medical loss ratio, or the percent of premiums spent on patient care, fell to 87.3% from 90.4% a year ago, below analysts' expectations of 88.9%, according to estimates compiled by LSEG.
Health insurers have been facing increased medical costs for the past two years, driven by high healthcare demand among older adults enrolled in Medicare Advantage plans.
CVS earned $2.25 per share in the first quarter ended March 31, compared with analysts' average estimate of $1.70.
It raised its adjusted full-year profit forecast to $6 to $6.20 per share from $5.75 to $6 previously.
Revenue from its pharmacy unit of $31.91 billion beat estimates of $30.96 billion. Its health services unit brought in revenue of $43.46 billion, also above estimates of $43.30 billion.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

38 minutes ago

• Business Insider

Elon Musk says xAI will retrain Grok: 'Far too much garbage'

When you're Elon Musk, you don't have to rely on centuries of prevailing human understanding — you can create your own. "We will use Grok 3.5 (maybe we should call it 4), which has advanced reasoning, to rewrite the entire corpus of human knowledge, adding missing information and deleting errors," Musk wrote on X on Friday night. Then, he said he would retrain Grok's latest model on that new base of knowledge to be free of proverbial waste. "Far too much garbage in any foundation model trained on uncorrected data," he added. Musk has for years endeavored to create products, like the rebranded Twitter and Grok, that are free from what he views as harmful mainstream constraints. Business Insider previously reported that Grok's army of "AI tutors" was training the bot on a host of dicey topics to compete with OpenAI's more "woke" ChatGPT. Musk on Saturday asked X users to respond to his post with examples of "divisive facts" that can be used in Grok's retraining. Gary Marcus, an AI hype critic and professor emeritus at New York University, compared Musk's effort to an Orwellian dystopia, which isn't the first time he's made the comparison. "Straight out of 1984. You couldn't get Grok to align with your own personal beliefs, so you are going to rewrite history to make it conform to your views," he wrote on X in response to Musk. A revamped Grok could have real-world impacts. In May, just as Musk was stepping back from his work in Washington, DC to refocus on his various companies, Reuters reported that DOGE was planning to expand its use of Grok to analyze government data. "They ask questions, get it to prepare reports, give data analysis," a source told Reuters, referring to how the bot was being used. Two other sources told the outlet that officials in the Department of Homeland Security had been encouraged to use it despite the fact that it hadn't been approved. A representative for the department told the New Republic that "DOGE hasn't pushed any employees to use any particular tools or products." Grok has also had security issues. In May, after what the company said was an "unauthorized modification" to its backend, the bot started to frequently refer to "white genocide" in South Africa. The company quickly resolved the issue and said it had conducted a "thorough investigation" and was "implementing measures to enhance Grok's transparency and reliability."

USA Today

2 hours ago

• USA Today

Customer data possibly leaked in Aflac cyberattack, the third insurance hack this month

The Aflac breach potentially impacted files with customers' Social Security numbers and health details. Insurance company Aflac disclosed this week that cybercriminals breached its U.S. network and may have accessed customers' personal information, the latest in a string of cyberattacks on insurance companies announced this month. Aflac, which provides home and life insurance and manages data for more than 50 million policyholders, said in a June 20 federal regulatory filing it identified suspicious activity on its U.S. network on June 12. The company said it believes it stopped the intrusion within hours of identifying it, calling the attack part of a 'cybercrime campaign against the insurance industry.' The breach potentially impacted files containing customers' personal information, such as Social Security numbers and health-related details. Aflac said it is investigating the breach with the help of third-party cybersecurity experts and has not yet determined how many customers were affected. An Aflac spokesperson told Reuters that the characteristics of the incident were consistent with the hacking group Scattered Spider, which has a reputation for targeting multiple companies in a single industry in waves. More: This is how you stop online trackers from collecting your health data Latest Tech News: Is TikTok getting banned? Trump says he'll 'probably' extend deadline again It's the largest insurance provider yet to disclose a breach this month, after cyberattacks on Erie Insurance and Philadelphia Insurance Companies disrupted their network operations. Aflac said the attack did not affect its systems and it is able to continue providing services as usual while it responds to the security breach. Contributing: Reuters. Kathryn Palmer is a national trending news reporter for USA TODAY. You can reach her at kapalmer@ and on X @KathrynPlmr.

Bloomberg

3 hours ago

• Bloomberg

Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.